{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:46:22Z","timestamp":1790725582867,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1053\/j.ajkd.2021.04.014","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:15:47Z","timestamp":1624518947000},"page":"793-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up"],"prefix":"10.1053","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-4549","authenticated-orcid":false,"given":"Reza","family":"Zonozi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah R.","family":"Huizenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian K.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushya","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Bernard","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank B.","family":"Cortazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Niles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1053\/j.ajkd.2021.04.014_bib2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2021.04.014_bib4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B\u2013associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.014_bib5","doi-asserted-by":"crossref","first-page":"F660","DOI":"10.1152\/ajprenal.00437.2004","article-title":"Experimental membranous nephropathy redux","volume":"289","author":"Cybulsky","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12882-017-0459-z","article-title":"Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series","volume":"18","author":"Cortazar","year":"2017","journal-title":"BMC Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2021.04.014_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1053\/j.ajkd.2021.04.014_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI83840","article-title":"Rituximab does not reset defective early B cell tolerance checkpoints","volume":"126","author":"Chamberlain","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1053\/j.ajkd.2021.04.014_bib12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.014_bib13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.014_bib14","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody\u2013associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"Van de Logt","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","article-title":"Effector and regulatory B cells in immune-mediated kidney disease","volume":"15","author":"Oleinika","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.04.014_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A\u00a0randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.014_bib17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2021.04.014_bib18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2021.04.014_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2021.04.014_bib20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2021.04.014_bib21","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"Van den Brand","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2021.04.014_bib22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"Van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.04.014_bib23","first-page":"139","article-title":"Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Cattran","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10.1053\/j.ajkd.2021.04.014_bib24","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyama","year":"1977","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.ajkd.2021.04.014_bib25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3899\/jrheum.150065","article-title":"Incidence of cyclophosphamide-induced urotoxicity and protective effect of mesna in rheumatic diseases","volume":"42","author":"Yilmaz","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1053\/j.ajkd.2021.04.014_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2021.04.014_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.41501","article-title":"Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease","volume":"73","author":"Zonozi","year":"2021","journal-title":"Arthritis Rheumatol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621006909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621006909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:39:11Z","timestamp":1759462751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621006909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0272638621006909"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.014","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}